BofA analyst Michael Cherny upgraded Cardinal Health (CAH) to Buy from Neutral with a price target of $145, up from $132. Cardinal’s organic growth in the core pharma segment has begun to outpace peers, notes the firm, which believes growth is likely to exceed Street expectations over the next year. Cardinal’s “impressive” growth is coming from new and existing customers, as well as a “unique PBM tailwind” that BofA estimates could contribute 2-3 percentage points to EPS growth through FY26, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health price target raised to $136 from $127 at Morgan Stanley
- Salesforce upgraded, ServiceNow downgraded: Wall Street’s top analyst calls
- Wells upgrades Cardinal Health to Equal Weight with thesis played out
- Cardinal Health upgraded to Equal Weight from Underweight at Wells Fargo
- Cardinal Health awarded $9B Defense Logistics Agency contract modification